Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

9.22USD
4:00pm EDT
Change (% chg)

$-0.27 (-2.85%)
Prev Close
$9.49
Open
$9.48
Day's High
$9.48
Day's Low
$9.20
Volume
40,197
Avg. Vol
61,042
52-wk High
$15.48
52-wk Low
$7.41

OMED.OQ

Chart for OMED.OQ

About

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab... (more)

Overall

Beta: 2.93
Market Cap(Mil.): $354.91
Shares Outstanding(Mil.): 37.40
Dividend: --
Yield (%): --

Financials

  OMED.OQ Industry Sector
P/E (TTM): -- 47.76 29.98
EPS (TTM): -3.05 -- --
ROI: -63.47 -2.36 13.08
ROE: -- 5.29 14.23

BRIEF-Oncomed Pharmaceuticals Q4 loss per share $0.60

* Oncomed Pharmaceuticals announces fourth quarter and full year 2016 financial results

Mar 08 2017

BRIEF-OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab

* OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab for the treatment of metastatic colorectal cancer patients Source text for Eikon: Further company coverage:

Jan 20 2017

BRIEF-Oncomed Pharmaceuticals reports Q3 financial results

* "We expect to file inds for two immuno-oncology programs in late 2016 though first half of 2017"

Nov 01 2016

More From Around the Web

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $164.71 -0.20
Astellas Pharma Inc (4503.T) ¥1,513 --
AstraZeneca plc (AZN.L) 4,960.00 -14.50
Bayer AG (BAYGn.DE) €106.90 +0.30
Bayer AG (BAYE.F) -- --
Celgene Corporation (CELG.OQ) $124.43 -0.43
Roche Holding Ltd. (ROG.S) CHF253.10 +0.20
Roche Holding Ltd. (RO.S) CHF253.00 +0.25
GlaxoSmithKline plc (GSK.L) 1,677.00 0.00
Johnson & Johnson (JNJ.N) $125.66 -0.14

Earnings vs. Estimates